STOCK TITAN

Voting Rights and Shares Capital of the Company

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

On June 11, 2024, Nanobiotix announced its updated voting rights and share capital, as per the requirements of the French Commercial Code and the French Financial Markets Authority. As of May 31, 2024, the company has 47,133,328 shares outstanding and a total of 48,904,378 voting rights. The theoretical total voting rights stand at 48,882,260. Nanobiotix will continue to publish monthly updates on its voting rights and share capital if there are changes in the figures previously disclosed.

Positive
  • The company maintains transparency by providing monthly updates on voting rights and share capital.
  • The announcement is compliant with regulatory requirements, reflecting good corporate governance.
Negative
  • No new business developments or financial performance indicators were included in the press release.
  • The figures provided do not indicate any growth or positive change in share or voting rights compared to previous disclosures.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, June 11, 2024 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date

Number of Shares
Outstanding
Total number of voting rights
Total voting rights,
theoretical
1
Total voting rights,
exercisable2
May 31, 2024

47,133,32848,904,37848,882,260


According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix 
Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Investor Relations Department
Craig West
SVP, Investor Relations
+1 (617) 583-0211
investors@nanobiotix.com
 
Media Relations 

FR –Ulysse Communication
Laurent Wormser
+ 33 (0)6 13 12 04 04
lwormser@ulysse-communication.com

Global –LifeSci Advisors
Kevin Gardner
+1 (617) 283-2856
kgardner@lifesciadvisors.com
 

_______________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

Attachment


FAQ

What is the total number of shares outstanding for NBTX as of May 31, 2024?

The total number of shares outstanding for NBTX as of May 31, 2024, is 47,133,328.

What are the total voting rights for NBTX as of May 31, 2024?

The total voting rights for NBTX as of May 31, 2024, are 48,904,378.

What are the theoretical voting rights for NBTX as of May 31, 2024?

The theoretical voting rights for NBTX as of May 31, 2024, are 48,882,260.

How often will Nanobiotix update the figures on voting rights and share capital?

Nanobiotix will update the figures on voting rights and share capital on a monthly basis if there are any changes.

Nanobiotix S.A. American Depositary Shares

NASDAQ:NBTX

NBTX Rankings

NBTX Latest News

NBTX Stock Data

189.62M
47.13M
13.56%
0.06%
Biotechnology
Healthcare
Link
United States of America
Paris